Edwards Lifesciences Corp
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net income | $356.4 | $351.0 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 36.6 | 38.5 |
| Non-cash operating lease cost | 6.1 | 7.7 |
| Stock-based compensation (Note 9) | 40.2 | 44.6 |
| Loss (gain) on investments, net | 12.5 | (1.0) |
| Deferred income taxes | (24.3) | (35.8) |
| Other | 3.6 | 0.5 |
| Changes in operating assets and liabilities: | ||
| Accounts and other receivables, net | (43.7) | (55.0) |
| Inventories | (0.1) | (69.5) |
| Accounts payable and accrued liabilities | (103.4) | (89.1) |
| Income taxes | 51.2 | (263.1) |
| Prepaid expenses and other current assets | 10.6 | 27.1 |
| Intellectual property agreement accrual | (36.7) | (5.2) |
| Other | (28.6) | (4.2) |
| Net cash provided by (used in) operating activities | 280.4 | (53.5) |
| Cash flows from investing activities | ||
| Capital expenditures | (56.0) | (65.3) |
| Purchases of held-to-maturity investments (Note 5) | (12.8) | (0.8) |
| Proceeds from held-to-maturity investments (Note 5) | 17.7 | 9.3 |
| Purchases of available-for-sale investments (Note 5) | (634.5) | (1.8) |
| Proceeds from available-for-sale investments (Note 5) | 827.9 | 157.3 |
| Investments in intangible assets | — | (20.0) |
| Payment for working capital adjustment for sale of product group (Note 4) | (36.3) | — |
| Payment for acquisition options | (3.0) | (10.8) |
| Issuances of notes receivable | (17.8) | (2.5) |
| Other | 0.1 | (2.3) |
| Net cash provided by investing activities | 85.3 | 63.1 |
| Cash flows from financing activities | ||
| Purchases of treasury stock | (258.6) | (0.2) |
| Equity forward contract related to accelerated share repurchase agreement (Note 10) | (50.0) | — |
| Proceeds from stock plans | 49.9 | 62.1 |
| Other | 0.7 | (0.2) |
| Net cash (used in) provided by financing activities | (258.0) | 61.7 |
| Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | (17.7) | 9.7 |
| Net increase in cash, cash equivalents, and restricted cash | 90.0 | 81.0 |
| Cash, cash equivalents, and restricted cash at beginning of period | 3,058.8 | 1,148.0 |
| Cash, cash equivalents, and restricted cash at end of period (Note 2) | $3,148.8 | $1,229.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.